|
Markers of bone turnover and calcium homeostasis during r-hPRL or placebo treatment |
||||
| Placebo |
r-hPRL |
|||
|
|
||||
| Before treatment |
After treatment |
Before treatment |
After treatment |
|
|
|
||||
| Deoxypyridinoline (nM/mM) |
7.2 ± 0.6 |
6.9 ± 0.7 |
9.5 ± 2.1 |
7.4 ± 1.8 |
| N-telopeptide (nM/mM Cr) |
45.3 ± 4.6 |
42.3 ± 5.6 |
35.6 ± 4.0 |
31.9 ± 4.1 |
| Bone specific alk phos (U/L) |
15.4 ± 1.3 |
17.5 ± 1.5* |
17.0 ± 2.2 |
18.1 ± 2.5 |
| Calcium (mmol/L) |
2.3 ± 0.03 |
2.4 ± 0.03* |
2.3 ± 0.03 |
2.4 ± 0.03* |
| Albumin (g/L) |
40 ± 1 |
43 ± 1* |
40 ± 1 |
42 ± 1 |
| Corrected calcium (mmol/L) |
2.4 ± 0.03 |
2.4 ± 0.03 |
2.4 ± 0.03 |
2.5 ± 0.05 |
| Phosphorus (mmol/L) |
1.2 ± 0.03 |
1.1 ± 0.03 |
1.0 ± 0.06 |
1.1 ± 0.06 |
| PTH (ng/L) |
45.7 ± 4.4 |
47.6 ± 4.5 |
46.8 ± 5.9 |
38.8 ± 6.2 |
| PTH-rP (pmol/L) |
0.33 ± 0.02 |
0.35 ± 0.04 |
0.30 ± 0.00 |
0.37 ± 0.05 |
| 1,25-(OH)2 Vit D (pmol/L) |
102.2 ± 7.0 |
102.2 ± 6.7 |
115.4 ± 17.5 |
117.6 ± 25.2 |
| Urinary Ca/Cr |
0.11 ± 0.02 |
0.11 ± 0.02 |
0.10 ± 0.02 |
0.15 ± 0.02 |
| Urinary Phos/Cr |
0.61 ± 0.07 |
0.61 ± 0.08 |
0.60 ± 0.07 |
0.59 ± 0.05 |
|
All results: mean ± SE * p < 0.05 within a group as indicated by the Tukey post hoc test. | ||||
Page-Wilson et al. International Breastfeeding Journal 2007 2:10 doi:10.1186/1746-4358-2-10 |
||||